What's Happening?
A recent umbrella review conducted by researchers in China has indicated that repeated low-level red-light therapy demonstrates short-term efficacy in managing pediatric myopia. The review, published in BMJ Open Ophthalmology, analyzed 22 systematic reviews
involving 73,993 participants. The findings suggest that red-light therapy significantly reduces axial elongation by an average of 0.24mm and spherical equivalent refraction (SER) progression by 0.49D. Subgroup analyses revealed that the treatment effect increased with longer follow-up periods, and sensitivity analyses confirmed the robustness of these findings. While red-light therapy is not widely adopted in the U.S. for this purpose, the review highlights its potential as an intervention, particularly for children and adolescents with high myopia and rapid axial elongation who may be intolerant to other treatments like low-dose atropine or orthokeratology lenses. The study emphasizes that while short-term benefits are evident, further research is needed to establish long-term efficacy and safety.
Why It's Important?
The findings from this umbrella review are significant for the field of pediatric ophthalmology, particularly given the global rise in myopia prevalence. If red-light therapy proves to be a safe and effective long-term solution, it could offer a valuable alternative or complementary treatment option for managing progressive myopia in children. This is especially crucial for patients who do not respond well to existing treatments, as high myopia carries a substantial lifetime risk of sight-threatening complications. The potential for a non-invasive therapy to slow the progression of myopia could reduce the burden of visual impairment and improve quality of life for many children. However, the current lack of long-term efficacy data and standardized safety reporting means that clinicians must carefully weigh the potential benefits against existing evidence gaps when discussing this therapy with patients and their families. The study also implicitly calls for more research in diverse populations, which could eventually influence treatment protocols and regulatory approvals in countries like the U.S.
What's Next?
The researchers recommend that future studies prioritize multiethnic, large-scale, and long-term follow-up investigations with standardized safety reporting and independent data sources. This will be crucial for strengthening the evidence base and informing clinical practice globally, including in the U.S. Clinicians are advised to discuss both the potential benefits and the current evidence gaps with patients and their families when considering red-light therapy. While the short-term results are promising, the absence of direct comparisons of adverse event rates with other interventions and the limited follow-up duration necessitate caution. Further research into combination therapies is also needed, as their safety and efficacy have not been systematically evaluated. The ongoing research will determine if red-light therapy can move from a promising intervention to a widely accepted and recommended treatment for pediatric myopia.
Beyond the Headlines
Beyond the immediate clinical implications, the growing interest in red-light therapy for myopia management highlights a broader trend in healthcare towards exploring non-pharmacological and non-invasive interventions. The study's emphasis on the need for long-term safety data also underscores the ethical considerations in pediatric treatments, where the potential for long-term side effects must be thoroughly understood before widespread adoption. The fact that much of the current research originates outside the U.S. also points to potential disparities in research focus and regulatory pathways for novel therapies. If future studies confirm long-term safety and efficacy, it could spur innovation in medical device development and potentially lead to new guidelines for myopia management, influencing healthcare policies and insurance coverage. This could also open avenues for further research into photobiomodulation for other ophthalmic conditions.













